[go: up one dir, main page]

WO2004042064A2 - Troubles du metabolisme des lipides - Google Patents

Troubles du metabolisme des lipides Download PDF

Info

Publication number
WO2004042064A2
WO2004042064A2 PCT/GB2003/004816 GB0304816W WO2004042064A2 WO 2004042064 A2 WO2004042064 A2 WO 2004042064A2 GB 0304816 W GB0304816 W GB 0304816W WO 2004042064 A2 WO2004042064 A2 WO 2004042064A2
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
sarlb
polypeptide
disorder
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2003/004816
Other languages
English (en)
Other versions
WO2004042064A3 (fr
Inventor
James Scott
Carol Christine Shoulders
Paul Simon Freemont
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ip2ipo Innovations Ltd
Original Assignee
Imperial College Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0226039A external-priority patent/GB0226039D0/en
Priority claimed from GB0226152A external-priority patent/GB0226152D0/en
Priority claimed from GB0305463A external-priority patent/GB0305463D0/en
Priority claimed from GB0323689A external-priority patent/GB0323689D0/en
Application filed by Imperial College Innovations Ltd filed Critical Imperial College Innovations Ltd
Priority to AU2003279461A priority Critical patent/AU2003279461A1/en
Publication of WO2004042064A2 publication Critical patent/WO2004042064A2/fr
Publication of WO2004042064A3 publication Critical patent/WO2004042064A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/42—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving phosphatase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity

Definitions

  • the present invention relates to isolated or recombinant nucleic acid molecules having one or more mutations linked to disorders of lipid metabolism such as Chylomicron Retention Disease (CMRD), Anderson's Disease (AD), Chylomicron
  • CMRD Chylomicron Retention Disease
  • AD Anderson's Disease
  • Chylomicron Chylomicron Retention Disease
  • CMRD Marinesco-Sjogren Syndrome
  • MSS Marinesco-Sjogren Syndrome
  • the present invention further provides for the diagnosis, prophylaxis and/or treatment of disorders of lipid metabolism, compositions comprising the nucleic acid molecule(s), the ⁇ oly ⁇ eptide(s) or at least one antibody that binds to the polypeptide(s), as well as vaccines and antibodies which are immunospecific for the polypeptides.
  • the invention further provides for a polynucleotide encoding short interfering RNA (siRNA) for inhibiting the expression of the nucleic acid molecule(s).
  • siRNA short interfering RNA
  • the small intestine is the site of absorption of dietary lipid (triglyceride, cholesteryl esters, phospholipids) and fat-soluble vitamins.
  • dietary lipid triglyceride, cholesteryl esters, phospholipids
  • the lipids enter the luminal surface of the absorptive cell as lipolytic products.
  • Chylomicrons (Cms) are assembled in the secretary pathways, and emerge from the abluminal surface for transport in intestinal lymphatics to the blood.
  • Cms are among the largest particles assembled and secreted from eukaryotic cells. Each of these particles carries a large neutral lipid load, surrounded by a single molecule of apolipoprotem (apo)B48, and a surface monolayer of phospholipids interspersed with free cholesterol.
  • apo apolipoprotem
  • the lipid provides an important source of energy, which can be stored as fat depots in time of nutritional abundance.
  • the remnants of peripheral Cm metabolism are cleared from the circulation by the liver, and further metabolized or re-packaged and secreted as triglyceride-rich, apoB-100 containing, very low density lipoproteins (VLDL). Elevated blood levels of apoB -containing lipoproteins are major risk factors for atheroscelerosis.
  • NLDL may associate with the metabolic syndrome of type II diabetes, insulin resistance, visceral obesity and dyslipidemia.
  • Apolipoprotein (apo)B is the major structural protein of both Cm and NLDL.
  • the small intestine produces the edited form of apoB mR ⁇ A that encodes apoB48, while the liver produces apoBlOO.
  • ApoB48 comprises the first 2152 amino acid residues of the 4536 amino acid apoBlOO protein.
  • apoB acquires a neutral lipid load in two steps. The first involves the formation of an apoB-free lipid droplet and a lightly lipidated apoB- containing particle.
  • the apoB-free lipid droplet(s) and the first-step apoB-containing particles fuse to produce a triglyceride-rich, apoB-containing lipoprotein, which may undergo further lipidation in the Golgi apparatus.
  • CMRD Chylomicron Retention Disease
  • AD Anderson's Disease
  • CMRD with MSS Marinesco-Sjogren Syndrome
  • the small GTPase Sarlb is obligatory for the transport of Cm through the secretory pathway of enterocytes.
  • Sarlb is defective in pure CMRD, AD, and CMRD with MSS. All three conditions are histologically characterised by an accumulation of Cm- like particles within large membrane-bound compartments of enterocytes.
  • Sarlb shares 90% amino acid sequence identity with Sari a, compared to 60% sequence identity with the yeast Sari homologue, Sarlp.
  • the small intestine and liver contain comparable levels of Sari a and Sarlb mR ⁇ A.
  • Sari proteins form an obligatory component of COPII-coated vesicles, which transport secretory and cell surface proteins (i.e.
  • ERGIC-clusters travel along microtubules.
  • the integral membrane protein Secl2 initiates the assembly of COPLT vesicles on the ER membranes by exchanging GDP on Sari for GTP. This exchange promotes the interaction of Sari with ER membrane lipids, the formation of a pre-budding complex through the recruitment of Sec23 complexed to Sec24 (Fig. 18F), and the capture of Secl3/31 heterodimers.
  • the five subunits i.e. Sari, Sec23/24 and Secl3/31 form the basic machinery required for budding and sorting of cargo into COPII-coated vesicles.
  • CMRD, AD and CMRD with MSS have a common genetic basis with phenotypic variation arising from mutational heterogeneity, and evaluated this by performing a genome-side screen in ten patients from six families.
  • an isolated or recombinant nucleic acid molecule comprising: a) the DNA sequence shown in Figure 2, 4, 6, 8, 10, 12a, 12b, 12c or 14 with or without the nucleotides boxed, or its RNA equivalent; b) a fragment of the sequence of a), the fragment comprising at least one of the mutations defined in Table 1 ; c) a sequence which is complementary to the sequence of a) or b); or d) a sequence which codes for the same polypeptide as the sequence a), b) or c).
  • the present invention provides an isolated or recombinant nucleic acid molecule comprising: a) a fragment of the DNA sequence shown in Figure 12a, or its RNA equivalent, the fragment including the mutation in bold and as defined in Table 1 ; b) a sequence which is complementary to the sequence of a); or c) a sequence which codes for the same polypeptide as the sequence a) or b).
  • the invention provides a method for screening for and/or diagnosis of a disorder of lipid metabolism in a subject, the method comprising the step of detecting and/or quantifying the amount of a nucleic acid molecule as defined in the first or second aspect in a biological sample obtained from said subject.
  • the mutation may be a missense mutation, such as G to A at position 109, G to A at position 409, T to A at position 537, G to A at position 536, or T to C at position 542 of the nucleic acid sequence as shown in Table 1.
  • the mutation may be a splice site mutation 349-1 G to C. This mutation can result in Exon 6 being skipped, or the failure to remove intron 5 such that GTAAGTTAA is added to Exon 5.
  • the mutation may be duplication of TTAC at 555-558.
  • the nucleic acid molecule of a) is mutated SARA2 gene.
  • the disorders of lipid metabolism may be CMRD, AD,
  • CMRD with MSS, obesity, insulin resistance, type II diabetes, atheroscelerosis, dyslipidemia, and/or hyperlipidemia.
  • RNA equivalent' when used above indicates that a given RNA molecule has a sequence which is complementary to that of a given DNA molecule, allowing for the fact that in RNA 'IP replaces 'T' in the genetic code.
  • the nucleic acid molecule of the present invention may be in isolated, recombinant or chemically synthetic form.
  • isolated or “recombinant” means any of a) amplified in vitro by, for example, polymerase chain reaction (PCR), b) recombinantly produced by cloning, c) purified by, for example, gel separation, or d) synthesised, such as by chemical synthesis.
  • PCR polymerase chain reaction
  • the nucleic acid molecules of the present invention may be synthesised using methods known in the art, such as using conventional chemical approaches or polymerase chain reaction (PCR) amplification.
  • the nucleic acid molecules of the present invention also permit the identification and cloning of mutated S ARA2 gene, for instance by screening cDNA libraries, genomic libraries or expression libraries.
  • the fragment of the sequence of a) above may comprise at least 15 nucleotides, at least
  • the fragment may comprise in the range of 18 to 20 nucleotides.
  • the fragment comprises a sequence that includes or spans the change in sequence resulting from the mutation.
  • the present invention includes nucleic acid molecules comprising a sequence complementary to the sequence as defined in (a) and (b) above.
  • nucleic acid molecules comprising a sequence complementary to the sequence as defined in (a) and (b) above.
  • both strands of a double stranded nucleic acid molecule are included within the scope of the present invention (whether or not they are associated with one another).
  • mRNA molecules and complementary DNA molecules e.g. cDNA molecules.
  • Manipulation of the DNA encoding a protein is a particularly powerful technique for both modifying proteins and for generating large quantities of protein for purification purposes. This may involve the use of PCR techniques to amplify a desired nucleic acid sequence.
  • sequence data provided herein can be used to design primers for use in PCR so that a desired sequence can be targeted and then amplified to a high degree.
  • a fourth aspect of the present invention provides a pair of nucleic acid primers, one of which can hybridise to the sense strand of the DNA sequence shown in Figure 2, 4, 6, 8, 10, 12a, 12b, 12c or 14 with or without the nucleotides boxed, or its RNA equivalent upstream of one of the mutations defined in Table 1, and the other of which can hybridise to the antisense strand of the DNA sequence shown in Figure 2, 4, 6, 8, 10, 12a, 12b, 12c or 14 with or without the nucleotides boxed, or its RNA equivalent respectively downstream of said mutation.
  • the or each primer will be at least five nucleotides long and will generally be at least ten nucleotides long (e.g. fifteen to twenty-five nucleotides long). In some cases, primers of at least thirty or at least thirty-five nucleotides in length may be used.
  • Chemical synthesis may be used to generate such primers. This may be automated. Relatively short sequences may be chemically synthesised and ligated together to provide a longer sequence.
  • a nucleic acid molecule as defined herein can also be used in hybridisation assays.
  • a nucleic acid molecule as defined herein, or subsequences thereof comprising at least 8 nucleotides, can be used as a hybridisation probe.
  • Hybridisation assays can be used for detection, prognosis, diagnosis, or monitoring of disorders of lipid metabolism.
  • such a hybridisation assay can be carried out by a method comprising contacting a patient sample containing nucleic acid with a nucleic acid probe capable of hybridising to a nucleic acid molecule of the first aspect, under conditions such that hybridisation can occur, and detecting or measuring any resulting hybridisation.
  • hybridising molecules are at least 10 nucleotides in length, are at least 25 or at least 50 nucleotides in length.
  • the hybridising molecules will hybridise to such nucleic acid molecules under stringent hybridisation conditions.
  • stringent hybridisation conditions is where attempted hybridisation is carried out at a temperature of from about 35°C to about 65°C using a salt solution which is about 0.9 molar.
  • the skilled person will be able to vary such conditions as appropriate in order to take into account variables such as probe length, base composition, type of ions present, etc.
  • relatively stringent conditions are used to form the duplexes, such as low salt or high temperature conditions.
  • highly stringent conditions means hybridisation to filter-bound DNA in 0.5 M NaHPO , 7% sodium dodecyl sulphate (SDS), 1 mM EDTA at 65 °C, and washing in O.lxSSC/0.1% SDS at 68 °C (Ausubel F.M. et al., eds., 1989, Current Protocols in Molecular Biology, Vol. I, Green Publishing Associates, Inc., and John Wiley & Sons, Inc., New York, at p.
  • hybridisation conditions can also be rendered more stringent by the addition of increasing amounts of formamide, to destabilise the hybrid duplex.
  • particular hybridisation conditions can be readily manipulated, and will generally be chosen depending on the desired results.
  • convenient hybridisation temperatures in the presence of 50% formamide are: 42 °C for a probe which is 95 to 100% identical to the portion of the nucleic acid molecule as defined herein, 37°C for 90 to 95% identity and 32 °C for 70 to 90% identity.
  • DNA fragments are generated, some of which will encode parts or the whole of a polypeptide encoded by the nucleic acid molecule of the first aspect.
  • the DNA may be cleaved at specific sites using various restriction enzymes. Alternatively, one may use DNAse in the presence of manganese to fragment the DNA, or the DNA can be physically sheared, as for example, by sonication.
  • the DNA fragments can then be separated according to size by standard techniques, including but not limited to agarose and polyacrylamide gel electrophoresis, column chromatography and sucrose gradient centrifugation.
  • DNA fragments can then be inserted into suitable vectors, including but not limited to plasmids, cosmids, bacteriophages lambda or T 4 , and yeast artificial chromosomes (YACs).
  • suitable vectors including but not limited to plasmids, cosmids, bacteriophages lambda or T 4 , and yeast artificial chromosomes (YACs).
  • the present invention provides the nucleic acid molecule of the first and or second aspect and/or the nucleic acid primers of the third aspect in the manufacture of a diagnostic for the diagnosis of a disorder of lipid metabolism.
  • a method for screening and/or diagnosis of a disorder of lipid metabolism in a subject comprising the steps of: a) a ⁇ -lministering a nucleic acid molecule of the first and/or second aspect to a biological sample obtained from a subject; and b) detecting and/or quantifying hybridisation of the nucleic acid molecule of the first and/or second aspect in the biological sample.
  • a method for screening for and or diagnosis of a disorder of lipid metabolism in a subject comprising the steps of: a) administering nucleic acid primers of the fourth aspect to a biological sample obtained from a subject; b) hybridising the nucleic acid primers to a nucleic acid molecule in the biological sample; c) amplifying the nucleic acid molecule with the nucleic acid primers; and d) comparing the amplified nucleic acid molecule with a nucleic acid molecule of the first aspect or the second aspect
  • hybridising nucleic acid molecules of the present invention can be used as anti-sense molecules to alter the expression of Sarlb by binding to complementary nucleic acid molecules. This technique can be used in anti-sense therapy.
  • mutant Sarlb polypeptide is inhibited by use of antisense nucleic acids.
  • the present invention provides a nucleic acid molecule comprising at least six nucleotides that is antisense to a portion of a nucleic acid molecule of the first aspect or to a portion of a nucleic acid molecule of the second aspect for use in the manufacture of a medicament for the treatment and/or prophylaxis of a disorder of lipid metabolism.
  • the nucleic acid may comprise at least 10 nucleotides, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, or at least 60 nucleotides.
  • the nucleic acid may comprise in the range of 18 to 20 nucleotides.
  • the nucleic acid molecule preferably includes at least one mutation as defined in Table 1.
  • the present invention provides a method for the prophylaxis and/or treatment of a disorder of lipid metabolism comprising administering a nucleic acid molecule comprising at least six nucleotides that is antisense to a portion of a nucleic acid molecule of the first aspect or to a portion of a nucleic acid molecule of the second aspect to a subject.
  • the nucleic acid molecule includes at least one mutation as defined in Table 1.
  • an "antisense" nucleic acid molecule refers to a nucleic acid capable of hybridising by virtue of some sequence complementarity to a portion of an RNA (preferably mRNA) derived from a nucleic acid molecule of the first aspect or of the second aspect.
  • the antisense nucleic acid may be complementary to a coding and/or non-coding region of a mRNA derived from a nucleic acid molecule of the first aspect.
  • Such antisense nucleic acids have utility as compounds that inhibit expression, and can be used in the treatment and/or prevention of disorders of lipid metabolism.
  • a hybridising nucleic acid molecule of the present invention may have a high degree of sequence identity along its length with a nucleic acid molecule within the scope of (a)- (d) in the first aspect and (a) -(c) of the second aspect above (e.g. at least 50%, at least 75% or at least 90% or 95% sequence identity).
  • sequence identity e.g. at least 50%, at least 75% or at least 90% or 95% sequence identity.
  • the "percent identity" of two nucleic acid sequences can be or is generally determined by aligning the sequences for optimal comparison purposes (e.g., gaps can be introduced in either sequences for best alignment with the other sequence) and comparing the nucleotides at corresponding positions.
  • the "best alignment” is an alignment of two sequences that results in the highest percent identity.
  • the determination of percent identity between two sequences can be accomplished using a mathematical algorithm known to those of skill in the art.
  • An example of a mathematical algorithm for comparing two sequences is the algorithm of Karlin and Altschul (1990) Proc. Natl. Acad. Sci. USA 87:2264-2268, modified as in Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA 90:5873-5877.
  • the NBLAST and XBLAST programs of Altschul, et al. (1990) J. Mol. Biol. 215:403-410 have incorporated such an algorithm.
  • Gapped BLAST can be utilized as described in Altschul et al. (1997) Nucleic Acids Res. 25:3389-3402.
  • PSI-Blast can be used to perform an iterated search which detects distant relationships between molecules (Id).
  • the default parameters of the respective programs e.g., XBLAST and NBLAST
  • the default parameters of the respective programs e.g., XBLAST and NBLAST
  • nucleic acid molecules of the present invention may have one or more of the following characteristics:
  • they may be provided in substantially pure form. Thus they may be provided in a form which is substantially free from contaminating proteins and/or from other nucleic acids;
  • introns may be provided with introns or without introns (e.g. as cDNA).
  • the DNA or RNA molecules may be in the form of aptamers
  • RNA interference is a process by which double stranded RNA can induce sequence specific post- transcriptional gene silencing or inhibition (WO01/75164).
  • the present invention provides a RNA molecule, or a polynucleotide encoding such a molecule, comprising a double stranded structure which has a nucleotide sequence which is identical to a portion of the sequence of Figure 2, 4, 6, 8, 10, 12a, 12b, 12c or 14 with or without the nucleotides boxed, or which includes the respective mutation defined in Table 1.
  • the present invention provides the use of a RNA molecule, or polynucleotide encoding such a molecule as defined in the tenth aspect, in the manufacture of a medicament for the prophylaxis and or treatment of a disorder of lipid metabolism.
  • the present invention provides a method for the prophylaxis and/or treatment of a disorder of lipid metabolism, comprising administering to a subject a RNA molecule or polynucleotide encoding such a molecule of the tenth aspect.
  • the RNA molecule may have a length of from 19 to 25 nucleotides or 19 to 23 nucleotides, or 21 nucleotides. At least one strand may have a 3 ' overlap from 1 to 5 nucleotides, 1 to 3 nucleotides or 2 nucleotides. At least one of the RNA strands may be blunt ended.
  • RNA may have a 3' overhang and the other strand can be blunt-ended or have an overhang. If both strands comprise an overhang, the length of the overhangs may be the same or different for each strand.
  • the RNA may comprise 21 nucleotide strands which are paired and which have overhangs of from about 1 to 3, particularly 2, nucleotides on both 3' ends of the RNA.
  • the 3' overhangs can be stabilised against degradation through the inclusion of purine nucleotides, such as adenosine or guanosine nucleotides.
  • pyrimidine nucleotides may be substituted by modified analogues, e.g., substitution of uridine 2 nucleotides 3' overhangs by 2'- deoxythymidine is tolerated and does not affect the efficiency of RNAi.
  • RNA molecules of this aspect of the present invention can be obtained using a number of techniques known to those of skill in the art.
  • the RNA can be chemically synthesised or recombinantly produced using methods known in the art.
  • the RNA is useful as a sequence-specific mediator of RNA degradation and thus, for inhibiting mRNA of the mutated SARA2 gene associated with or causative of disorders of lipid metabolism.
  • 21-23 nt RNAs can be produced and tested for their ability to mediate RNAi in a cell, such as a human or other primate cell.
  • 21-23 nt human RNA molecules shown to mediate RNAi can be tested, if desired, in an appropriate animal model to further assess their in vivo effectiveness. Additional copies of 21-23 nt RNAs shown to mediate RNAi can then be produced.
  • dsRNA can be used in the methods of the present invention, provided that it has sufficient homology to the targeted portion to which it is identical in sequence to mediate RNAi.
  • the dsRNA for use in the present invention corresponds to a nucleic acid molecule as defined above.
  • the RNA can be introduced into human cells or a human in order to mediate RNA interference in the cells or in cells in the individual, such as to prevent or treat a disorder of lipid metabolism.
  • the mutated SARA2 gene is targeted, and the corresponding mRNA is degraded by RNAi.
  • an RNA of about 21 to about 23 nucleotides that targets the corresponding mRNA (the mRNA of the targeted gene) for degradation is introduced into the cell or organism.
  • the cell or organism is maintained under conditions under which degradation of the corresponding mRNA occurs, thereby mediating RNA interference of the mRNA of the gene in the cell or organism.
  • the factors needed to mediate RNAi are introduced into such a cell or the expression of the factors is induced in such a cell.
  • an ex vivo method may be used to treat cells from an individual to degrade mutated SARA2 gene that causes or is associated with a disorder of lipid metabolism.
  • cells to be treated are obtained from the individual using known methods (e.g., phlebotomy or collection of bone marrow) and RNAs that mediate degradation of the corresponding mRNA(s) are introduced into the cells, which are then re-introduced into the individual. If necessary, biochemical components needed for RNAi to occur can also be introduced into the cells.
  • the present invention provides an isolated or recombinant polypeptide comprising: a) the amino acid sequence shown in Figure 3, 5, 7, 9, 11, 13a, 13b or 15; or b) a fragment of a polypeptide as defined in a), which is at least 5 amino acids long and includes at least one of the mutations defined in Table 1.
  • polypeptides of the present invention can be coded for by a large variety of nucleic acid molecules, taking into account the well known degeneracy of the genetic code. All of these molecules are within the scope of the present invention. They can be inserted into vectors and cloned to provide large amounts of DNA or RNA for further study. Suitable vectors may be introduced into host cells to enable the expression of polypeptides used in the present invention using techniques known to the person skilled in the art.
  • polypeptides or fragments thereof of the present invention may be provided in isolated or recombinant form, and may be fused to other moieties.
  • the polypeptides or fragments thereof may be provided in substantially pure form, that is to say free, to a substantial extent, from other proteins.
  • a polypeptide may be provided in a composition in which it is the predominant component present (i.e. it is present at a level of at least 50%; preferably at least 75%, at least 90%, or at least 95%; when determined on a weight/weight basis excluding solvents or carriers).
  • a polypeptide within the scope of a may consist of the particular amino acid sequence given in Figure 3, 5, 7, 9, 11, 13a, 13b or 15 or may have an additional N-terrninal and/or an additional C-te ⁇ ninal amino acid sequence. Additional N-terminal or C-terminal sequences may be provided for various reasons. Techniques for providing such additional sequences are well known in the art.
  • Additional sequences may be provided in order to alter the characteristics of a particular polypeptide. This can be useful in improving expression or regulation of expression in particular expression systems.
  • an additional sequence may provide some protection against proteolytic cleavage. This has been done for the hormone Somatostatin by fusing it at its N-te ⁇ ninus to part of the ⁇ galactosidase enzyme (Itakwa etal, Science 198: 105-63 (1977)).
  • a fusion protein may be provided in which a polypeptide is linked to a moiety capable of being isolated by affinity chromatography.
  • the moiety may be an antigen or an epitope and the affinity column may comprise immobihsed antibodies or immobihsed antibody fragments which bind to said antigen or epitope (desirably with a high degree of specificity).
  • the fusion protein can usually be eluted from the column by addition of an appropriate buffer.
  • N-terminal or C-terminal sequences may, however, be present simply as a result of a particular technique used to obtain a polypeptide and need not provide any particular advantageous characteristic to the polypeptide.
  • Such polypeptides are within the scope of the present invention.
  • the resultant polypeptide should exhibit the immunological or biological activity of the polypeptide having the amino acid sequence shown in Figure 3, 5, 7, 9, 11, 13a, 13b or 15.
  • Feature b) of the thirteenth aspect of the present invention therefore covers fragments of polypeptides a) above, the fragments including at least one of the mutations defined in Table 1.
  • “Fragment” refers to a peptide or polypeptide comprising an amino acid sequence of at least 5 amino acid residues (preferably, at least 10 amino acid residues, at least 15 amino acid residues, at least 20 amino acid residues, at least 25 amino acid residues, at least 40 amino acid residues, at least 50 amino acid residues, at least 60 amino residues, at least 70 amino acid residues, at least 80 amino acid residues, at least 90 amino acid residues, at least 100 amino acid residues, at least 125 amino acid residues, at least 150 amino acid residues, at least 175 amino acid residues, at least 200 amino acid residues, or at least 250 amino acid residues) of the amino acid sequence of a).
  • the fragment may or may not possess a functional activity of the polypeptide defined in a).
  • a polypeptide as defined herein may be useful as antigenic material, and may be used in the production of vaccines for treatment or prophylaxis disorders of lipid metabolism.
  • Such material can be "antigenic” and/or “immunogenic”.
  • antigenic is taken to mean that the protein is capable of being used to raise antibodies or indeed is capable of inducing an antibody response in a subject.
  • immunogenic is taken to mean that the protein is capable of ehciting a protective immune response in a subject.
  • the protein may be capable of not only generating an antibody response but, in addition, non-antibody based immune responses.
  • the fragments of the present invention may include one or more such epitopic regions or be sufficiently similar to such regions to retain their antigenic/immunogenic properties.
  • the degree of identity is perhaps irrelevant, since they may be 100% identical to a particular part of a protein or polypeptide, homologue or derivative as described herein. The key issue may be that the fragment retains the antigenic/immunogenic properties of the polypeptide from which it is derived.
  • Fragments may possess at least a degree of the antigenicity/immunogenicity of the polypeptide from which they are derived.
  • the present invention provides the use of a polypeptide as defined in the thirteenth aspect in the manufacture of a medicament for the treatment and/or prophylaxis of a disorder of lipid metabolism, wherein the medicament is a vaccine.
  • the vaccine optionally comprises one or more suitable adjuvants.
  • suitable adjuvants include inorganic gels, such as aluminium hydroxide, and water-in-oil emulsions, such as incomplete Freund's adjuvant. Other useful adjuvants will be well known to the skilled person.
  • the present invention provides:
  • a method for the treatment and/or prophylaxis of a disorder of lipid metabolism in a subject, or of vaccinating a subject against a disorder of lipid metabolism which comprises the step of administering to the subject an effective amount of a polypeptide as defined herein, preferably as a vaccine.
  • a further aspect provides a method of diagnosis of a disorder of lipid metabolism in a subject, the method comprising detecting and/or quantifying the amount of a polypeptide as defined above in a biological sample obtained from said subject.
  • an antibody is used for detecting and/or quantifying the amount of a polypeptide as defined in the thirteenth aspect of the invention in a biological sample obtained from said subject.
  • binding of antibody in tissue sections can be used to detect aberrant polypeptide localisation or an aberrant level of polypeptide.
  • antibody to a polypeptide as defined herein can be used to assay a patient tissue for the level of the polypeptide where an aberrant level of polypeptide is indicative of a disorder of lipid metabolism.
  • an "aberrant level” means a level that is increased or decreased compared with the level in a subject free from the disorder of lipid metabolism or a reference level. If desired, the comparison can be performed with a matched sample from the same subject, taken from a portion of the body not affected by the disorder of lipid metabolism.
  • tissue from a subject is analysed for quantitative detection of a polypeptide as defined in the thirteenth aspect, wherein a change in abundance of the polypeptide in the tissue from the subject relative to tissue from a subject or subjects free from a disorder of lipid metabolism (e.g., a control sample or a previously determined reference range) indicates the presence of a disorder of lipid metabolism.
  • a disorder of lipid metabolism e.g., a control sample or a previously determined reference range
  • Suitable immunoassays include, without limitation, competitive and non-competitive assay systems using techniques such as western blots, radioimmunoassays, ELISA (enzyme linked immunosorbent assay), "sandwich” immunoassays, immunoprecipitation assays, precipitin reactions, gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays, complement-fixation assays, immunoradiometric assays, fluorescent immunoassays and protein A immunoassays.
  • competitive and non-competitive assay systems using techniques such as western blots, radioimmunoassays, ELISA (enzyme linked immunosorbent assay), "sandwich” immunoassays, immunoprecipitation assays, precipitin reactions, gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays, complement-fixation assays, immunoradiometric assays, fluorescent immunoassays and
  • the present invention provides an antibody which binds to at least one polypeptide as defined in the thirteenth aspect.
  • the antibody binds specifically to a polypeptide as defined in the thirteenth aspect, for example by recognising a region encoding the mutation.
  • the present invention provides the use of an antibody of the invention for screening for and/or diagnosis of a disorder of lipid metabolism.
  • the present invention provides a method for the screening for and/or diagnosis of a disorder of lipid metabolism in a subject, which comprises detecting and/or quantifying the amount of a polypeptide as defined in the thirteenth aspect in a biological sample obtained from said subject using an antibody of the invention.
  • the present invention provides a method for the prophylaxis and/or treatment of a disorder of lipid metabolism in a subject, which comprises administering to said subject a therapeutically effective amount of an antibody of the invention.
  • the present invention provides the use of an antibody of the invention in the preparation of a medicament for use in the prophylaxis and/or treatment of a disorder of lipid metabolism.
  • Preferred antibodies bind specifically to polypeptides of the present invention so that they can be used to purify and or inhibit the activity of such polypeptides.
  • the antibodies maybe monoclonal or polyclonal.
  • the polypeptide of the present invention may be used as an immunogen to generate antibodies which immunospecifically bind such an immunogen.
  • Antibodies of the invention include, but are not limited to polyclonal, monoclonal, bispecific, humanised or chimeric antibodies, single chain antibodies, Fab fragments and F(ab') 2 fragments, fragments produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies, and epitope-binding fragments of any of the above.
  • antibody refers to immunoglobulin molecules and inununologically-active portions of immunoglobuhn molecules, i.e., molecules that contain an antigen binding site that specifically binds an antigen.
  • the immunoglobuhn molecules of the invention can be of any class (e.g., IgG, IgE, IgM, IgD and IgA) or subclass of immunoglobulin molecule.
  • screening for the desired antibody can be accomplished by techniques known in the art, e.g. ELISA (enzyme-linked immunosorbent assay).
  • ELISA enzyme-linked immunosorbent assay
  • an antibody that specifically binds a first polypeptide homologue but which does not specifically bind to (or binds less avidly to) a second polypeptide homologue one can select on the basis of positive binding to the first polypeptide homologue and a lack of binding to (or reduced binding to) the second polypeptide homologue.
  • mAbs monoclonal antibodies directed toward a polypeptide used in the invention
  • any technique which provides for the production of antibody molecules by continuous cell lines in culture may be used.
  • Such antibodies may be of any immunoglobulin class including IgG, IgM, IgE, IgA, IgD and any subclass thereof.
  • the hybridoma producing the mAbs used in the invention may be cultivated in vitro or in vivo.
  • monoclonal antibodies can be produced in germ-free animals utilising known technology (PCT/US90/02545).
  • the monoclonal antibodies include but are not limited to human monoclonal antibodies and chimeric monoclonal antibodies (e.g., human-mouse chimeras).
  • a chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a human immunoglobulin constant region and a variable region derived from a murine mAb.
  • Humanised antibodies are antibody molecules from non-human species having one or more complementarity determining regions (CDRs) from the non-human species and a framework region from a human immunoglobulin molecule. (See, e.g., U.S. Patent No. 5,585,089).
  • Chimeric and humanised monoclonal antibodies can be produced by recombinant DNA techniques known in the art, for example using methods described in WO 87/02671; EP-A-184,187; EP-A-171,496; EP-A-173,494; WO 86/01533; U.S. Patent No. 4,816,567; EP-A-125,023; Better et al, 1988, Science 240:1041-1043; Liu et al, 1987, Proc. Natl. Acad. Sci. USA 84:3439-3443; Liu et al, 1987, J. Immunol. 139:3521-3526; Sun et al, 1987, Proc. Natl. Acad. Sci.
  • Fully human antibodies are particularly desirable for therapeutic treatment of human patients.
  • Such antibodies can be produced using transgenic mice which are incapable of expressing endogenous immunoglobulin heavy and light chain genes, but which can express human heavy and light chain genes.
  • the transgenic mice are immunised in the normal fashion with a selected antigen, e.g., all or a portion of a polypeptide used in the invention.
  • Monoclonal antibodies directed against the antigen can be obtained using conventional hybridoma technology.
  • the human immunoglobulin transgenes harboured by the transgenic mice rearrange during B cell differentiation, and subsequently undergo class switching and somatic mutation.
  • Completely human antibodies which recognise a selected epitope can be generated using a technique referred to as "guided selection.”
  • a selected non- human monoclonal antibody e.g., a mouse antibody
  • the antibodies used in the present invention can also be generated using various phage display methods known in the art.
  • phage display methods functional antibody domains are displayed on the surface of phage particles which carry the polynucleotide sequences encoding them.
  • phage can be utilised to display antigen binding domains expressed from a repertoire or combinatorial antibody library (e.g., human or murine).
  • Phage expressing an antigen binding domain that binds the antigen of interest can be selected or identified with antigen, e.g., using labelled antigen or antigen bound or captured to a solid surface or bead.
  • Phage used in these methods are typically filamentous phage including fd and Ml 3 binding domains expressed from phage with Fab, Fv or disulphide stabilised Fv antibody domains recombinantly fused to either the phage gene HI or gene NIII protein.
  • Phage display methods that can be used to make the antibodies used in the present invention include those disclosed in Brinkman et al, J. Immunol Methods
  • the antibody coding regions from the phage can be isolated and used to generate whole antibodies, including human antibodies, or any other desired antigen binding fragment, and expressed in any desired host, including mammalian cells, insect cells, plant cells, yeast, and bacteria, e.g., as described in detail below.
  • Fab, Fab' and F(ab')2 fragments can also be employed using methods known in the art such as those disclosed in WO 92/22324; Mullinax et al, BioTechniques 12(6):864-869 (1992); and Sawai et al, AJRI 34:26-3A (1995); and Better et al, Science 240:1041-1043 (1988).
  • the invention further provides for the use of bispecific antibodies, which can be made by methods known in the art.
  • Traditional production of full length bispecific antibodies is based on the coexpression of two immunoglobulin heavy chain-light chain pairs, where the two chains have different specificities (Milstein et al, 1983, Nature 305:537-539). Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a potential mixture of 10 different antibody molecules, of which only one has the correct bispecific structure. Purification of the correct molecule, which is usually done by affinity chromatography steps, is rather cumbersome, and the product yields are low. Similar procedures are disclosed in WO 93/08829, and in Traunecker et al, 1991, EMBO J. 10:3655-3659.
  • antibody variable domains with the desired binding specificities are fused to immunoglobulin constant domain sequences.
  • the fusion preferably is with an immunoglobulin heavy chain constant domain, comprising at least part of the hinge, CH2, and CH3 regions. It is preferred to have the first heavy-chain constant region (CHI) containing the site necessary for light chain binding, present in at least one of the fusions.
  • DNAs encoding the immunoglobulin heavy chain fusions and, if desired, the immunoglobulin light chain are inserted into separate expression vectors, and are co-transfected into a suitable host organism.
  • the bispecific antibodies are composed of a hybrid immunoglobulin heavy chain with a first binding specificity in one arm, and a hybrid immunoglobulin heavy chain-light chain pair (providing a second binding specificity) in the other arm. It was found that this asymmetric structure facilitates the separation of the desired bispecific compound from unwanted immunoglobulin chain combinations, as the presence of an immunoglobulin light chain in only one half of the bispecific molecule provides for a facile way of separation. This approach is disclosed in WO 94/04690. For further details for generating bispecific antibodies see, for example, Suresh et al, Methods in Enzymology, 1986, 121:210.
  • the invention provides for the use of functionally- active fragments, derivatives or analogues of the anti-polypeptide immunoglobulin molecules.
  • “Functionally-active” means that the fragment, derivative or analogue is able to elicit anti-anti-idiotype antibodies (i.e., tertiary antibodies) that recognise the same antigen that is recognised by the antibody from which the fragment, derivative or analogue is derived.
  • the antigenicity of the idiotype of the immunoglobulin molecule may be enhanced by deletion of framework and CDR sequences that are C-terminal to the CDR sequence that specifically recognises the antigen.
  • synthetic peptides containing the CDR sequences can be used in binding assays with the antigen by any binding assay method known in the art.
  • the present invention provides antibody fragments such as, but not limited to, F(ab') 2 fragments and Fab fragments.
  • Antibody fragments which recognise specific epitopes may be generated by known techniques.
  • F(ab') 2 fragments consist of the variable region, the light chain constant region and the CHI domain of the heavy chain and are generated by pepsin digestion of the antibody molecule.
  • Fab fragments are generated by reducing the disulphide bridges of the F(ab') 2 fragments.
  • the invention also provides heavy chain and light chain dimmers of the antibodies of the invention, or any minimal fragment thereof such as Fvs or single chain antibodies (SCAs) (e.g., as described in U.S.
  • the invention provides fusion proteins of the immunoglobulins of the invention (or functionally active fragments thereof), for example in which the immunoglobulin is fused via a covalent bond (e.g., a peptide bond), at either the N- terminus or the C-terminus to an amino acid sequence of another protein (or portion thereof, preferably at least 10, 20 or 50 amino acid portion of the protein) that is not the immunoglobulin.
  • a covalent bond e.g., a peptide bond
  • the immunoglobulin, or fragment thereof is covalently linked to the other protein at the N-terminus of the constant domain.
  • such fusion proteins may facilitate purification, increase half-life in vivo, and enhance the delivery of an antigen across an epithelial barrier to the immune system.
  • the immunoglobulins used in the invention include analogues and derivatives that are either modified, i.e., by the covalent attachment of any type of molecule as long as such covalent attachment that does not impair immunospecific binding.
  • the derivatives and analogues of the immunoglobulins include those that have been further modified, e.g., by glycosylation, acetylation, pegylation, phosphylation, amidation, derivatisation by known protecting/blocking groups, proteolytic cleavage, linkage to a cellular ligand or other protein, etc. Any of numerous chemical modifications may be carried out by known techniques, including, but not limited to specific chemical cleavage, acetylation, formylation, etc. Additionally, the analogue or derivative may contain one or more non-classical amino acids.
  • the foregoing antibodies can be used in methods known in the art relating to the localisation and activity of the polypeptides of the invention, e.g., for imaging or radioimaging these proteins, measuring levels thereof in appropriate physiological samples, in diagnostic methods, etc. and for radiotherapy.
  • the antibodies of the invention can be produced by any method known in the art for the synthesis of antibodies, in particular, by chemical synthesis or by recombinant expression, and are preferably produced by recombinant expression technique.
  • a nucleic acid encoding the antibody may be assembled from chemically synthesised oligonucleotides (e.g., as described in Kutmeier et al, 199 A, BioTechniques 17:242), which, briefly, involves the synthesis of overlapping oligonucleotides containing portions of the sequence encoding antibody, annealing and ligation of those oligonucleotides, and then amplification of the ligated oligonucleotides by PCR.
  • the nucleic acid encoding the antibody may be obtained by cloning the antibody. If a clone containing the nucleic acid encoding the particular antibody is not available, but the sequence of the antibody molecule is known, a nucleic acid encoding the antibody may be obtained from a suitable source (e.g., an antibody cDNA library, or cDNA library generated from any tissue or cells expressing the antibody) by PCR amplification using synthetic primers hybridisable to the 3' and 5' ends of the sequence or by cloning using an oligonucleotide probe specific for the particular gene sequence.
  • a suitable source e.g., an antibody cDNA library, or cDNA library generated from any tissue or cells expressing the antibody
  • antibodies specific for a particular antigen may be generated by any method known in the art, for example, by immunising an animal, such as a rabbit, to generate polyclonal antibodies or, more preferably, by generating monoclonal antibodies.
  • a clone encoding at least the Fab portion of the antibody may be obtained by screening Fab expression libraries (e.g., as described in Huse et al., 1989, Science 246:1275-1281) for clones of Fab fragments that bind the specific antigen or by screening antibody libraries (See, e.g., Clackson et al, 1991, Nature 352:624; Hane et al, 1997 Proc. Natl. Acad. Sci. USA 94:4937).
  • nucleic acid encoding at least the variable domain of the antibody molecule may be introduced into a vector containing the nucleotide sequence encoding the constant region of the antibody molecule (see, e.g., WO 86/05807; WO 89/01036; and U.S. Patent No. 5,122,464).
  • Vectors containing the complete light or heavy chain for co-expression with the nucleic acid to allow the expression of a complete antibody molecule are also available.
  • the nucleic acid encoding the antibody can be used to introduce the nucleotide substitution(s) or deletion(s) necessary to substitute (or delete) the one or more variable region cysteine residues participating in an intrachain disulphide bond with an amino acid residue that does not contain a sulphydryl group.
  • Such modifications can be carried out by any method known in the art for the introduction of specific mutations or deletions in a nucleotide sequence, for example, but not limited to, chemical mutagenesis, in vitro site directed mutagenesis (Hutchinson et al, 1978, J. Biol. Chem. 253:6551), PCR based methods, etc.
  • a chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived from a murine mAb and a human antibody constant region, e.g., humanised antibodies.
  • the vector for the production of the antibody molecule may be produced by recombinant D ⁇ A technology using techniques well known in the art.
  • methods for preparing the polypeptides used in the invention by expressing nucleic acid containing the antibody molecule sequences are described herein. Methods which are well known to those skilled in the art can be used to construct expression vectors containing an antibody molecule coding sequences and appropriate transcriptional and translational control signals. These methods include, for example, in vitro recombinant D ⁇ A techniques, synthetic techniques, and in vivo genetic recombination. See, for example, the techniques described in Sambrook et al.
  • the expression vector is transferred to a host cell by conventional techniques and the transfected cells are then cultured by conventional techniques to produce an antibody of the invention.
  • the host cells used to express a recombinant antibody of the invention may be either bacterial cells such as Escherichia coli, or, preferably, eukaryotic cells, especially for the expression of whole recombinant antibody molecule.
  • mammalian cells such as Chinese hamster ovary cells (CHO), in conjunction with a vector such as the major intermediate early gene promoter element from human cytomegalo virus is an effective expression system for antibodies (Foecking et al, 198, Gene 45:101; Cockett et al, 1990, Bio/Technology 8:2).
  • host-expression vector systems may be utilised to express an antibody molecule of the invention.
  • Such host-expression systems represent vehicles by which the coding sequences of interest may be produced and subsequently purified, but also represent cells which may, when transformed or transfected with the appropriate nucleotide coding sequences, express the antibody molecule of the invention in situ.
  • These include but are not limited to microorganisms such as bacteria (e.g., E. coli, B.
  • subtilis transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing antibody coding sequences; yeast (e.g., Saccharomyces, Pichia) transformed with recombinant yeast expression vectors containing antibody coding sequences; insect cell systems infected with recombinant virus expression vectors (e.g., baculo virus) containing the antibody coding sequences; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMN) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing antibody coding sequences; or mammalian cell systems (e.g., COS, CHO, BHK, 293, 3T3 cells) harbouring recombinant expression constructs containing promoters derived from the genome of mammalian cells (e.g., metallothionein promoter) or from
  • a number of expression vectors may be advantageously selected depending upon the use intended for the antibody molecule being expressed.
  • vectors which direct the expression of high levels of fusion protein products that are readily purified may be desirable.
  • Such vectors include, but are not limited, to the E. coli expression vectorpUR278 (Ruther et al, 1983, EMBOJ. 2:1791), in which the antibody coding sequence may be ligated individually into the vector in frame with the lac Z coding region so that a fusion protein is produced; pJJSf vectors (Inouye & Inouye, 1985, Nucleic Acids Res.
  • pGEX vectors may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST).
  • GST glutathione S-transferase
  • fusion proteins are soluble and can easily be purified from lysed cells by adsorption and binding to a matrix glutathione-agarose beads followed by elution in the presence of free glutathione.
  • the pGEX vectors are designed to include thrombin or factor Xa protease cleavage sites so that the cloned target gene product can be released from the GST moiety.
  • Autographa calif ornica nuclear polyhedrosis virus (Ac ⁇ PN) is used as a vector to express foreign genes.
  • the virus grows in Spodopterafrugiperda cells.
  • the antibody coding sequence may be cloned individually into non-essential regions (for example, the polyhedrm gene) of the virus and placed under control of an Ac ⁇ PN promoter (for example, the polyhedrin promoter).
  • an Ac ⁇ PN promoter for example, the polyhedrin promoter.
  • a number of viral-based expression systems e.g., an adeno virus expression system
  • an adeno virus expression system may be utilised.
  • a host cell strain may be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Such modifications (e.g., glycosylation) and processing (e.g., cleavage) of protein products maybe important for the function of the protein.
  • cells lines that stably express an antibody of interest can be produced by transfecting the cells with an expression vector comprising the nucleotide sequence of the antibody and the nucleotide sequence of a selectable (e.g., neomycin or hygromycin), and selecting for expression of the selectable marker.
  • a selectable e.g., neomycin or hygromycin
  • Such engineered cell lines may be particularly useful in screening and evaluation of compounds that interact directly or indirectly with the antibody molecule.
  • the expression levels of the antibody molecule can be increased by vector amplification (for a review, see Bebbington and Hentschel, The use of vectors based on gene amplification for the expression of cloned genes in mammalian cells in DNA cloning, Nol.3. (Academic Press, New York, 1987)).
  • vector amplification for a review, see Bebbington and Hentschel, The use of vectors based on gene amplification for the expression of cloned genes in mammalian cells in DNA cloning, Nol.3. (Academic Press, New York, 1987)).
  • a marker in the vector system expressing antibody is amplifiable
  • increase in the level of inhibitor present in culture of host cell will increase the number of copies of the marker gene. Since the amplified region is associated with the antibody gene, production of the antibody will also increase (Crouse et al, 1983, Mol. Cell. Biol. 3:257).
  • the host cell may be co-transfected with two expression vectors of the invention, the first vector encoding a heavy chain derived polypeptide and the second vector encoding a light chain derived polypeptide.
  • the two vectors may contain identical selectable markers which enable equal expression of heavy and light chain polypeptides.
  • a single vector may be used which encodes both heavy and light chain polypeptides. In such situations, the light chain should be placed before the heavy chain to avoid an excess of toxic free heavy chain (Proudfoot, 1986, Nature 322:52; Kohler, 1980, Proc. Natl. Acad. Sci. USA 77:2197).
  • the coding sequences for the heavy and light chains may comprise cDNA or genomic DNA.
  • the antibody molecule used in the invention may be purified by any method known in the art for purification of an antibody molecule, for example, by chromatography (e.g., ion exchange chromatography, affinity chromatography such as with protein A or specific antigen, and sizing column chromatography), centrifugation, differential solubility, or by any other standard technique for the purification of proteins.
  • chromatography e.g., ion exchange chromatography, affinity chromatography such as with protein A or specific antigen, and sizing column chromatography
  • centrifugation e.g., centrifugation, differential solubility, or by any other standard technique for the purification of proteins.
  • any fusion protein may be readily purified by utilising an antibody specific for the fusion protein being expressed.
  • a system described by Janknecht et al. allows for the ready purification of non-denatured fusion proteins expressed in human cell lines (Janknecht et al, 1991, Proc. Natl. Acad. Sci. USA 88:8972-897).
  • the gene of interest is subcloned into a vaccinia recombination plasmid such that the open reading frame of the gene is translationally fused to an amino-terminal tag consisting of six histidine residues.
  • the tag serves as a matrix binding domain for the fusion protein. Extracts from cells infected with recombinant vaccinia virus are loaded onto Ni 2+ nitriloacetic acid-agarose columns and histidine-tagged proteins are selectively eluted with imidazole-containing buffers.
  • antibodies of the invention or fragments thereof are conjugated to a diagnostic or therapeutic moiety.
  • the antibodies can be used for diagnosis or to determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling the antibody to a detectable substance.
  • detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, radioactive nuclides, positron emitting metals (for use in positron emission tomography), and nonradioactive paramagnetic metal ions. See generally U.S. Patent No.4,741,900 for metal ions which can be conjugated to antibodies for use as diagnostics according to the present invention.
  • Suitable enzymes include horseradish peroxidase, alkaline phosphatase, beta-galactosidase, or acetylcholinesterase;
  • suitable prosthetic groups include streptavidin, avidin and biotin;
  • suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride and phycoerythrin;
  • suitable luminescent materials include luminol;
  • suitable bioluminescent materials include luciferase, luciferin, and aequorin;
  • radioactive nuclides include I, I, In and Tc.
  • An antibody can be conjugated to a second antibody to form an antibody heteroconjugate as described in U.S. Patent No. 4,676,980.
  • An antibody can be used as a therapeutic that is administered alone.
  • polypeptides, nucleic acid molecules and antibodies find use in the treatment and/or prophylaxis of disorders of lipid metabolism.
  • the present invention provides a pharmaceutical formulation comprising at least one polypeptide, nucleic acid molecule or antibody of the invention, optionally together with one or more pharmaceutically acceptable excipients, carriers or diluents.
  • the pharmaceutical formulation is for use as a vaccine and so any additional components will be acceptable for vaccine use.
  • one or more suitable adjuvants may be added to such vaccine preparations.
  • the medicament will usually be supplied as part of a sterile, pharmaceutical composition which will normally include a pharmaceutically acceptable carrier.
  • This pharmaceutical composition maybe in any suitable form (depending upon the desired method of administering it to a patient).
  • unit dosage form will generally be provided in a sealed container and may be provided as part of a kit.
  • a kit would normally (although not necessarily) include instructions for use. It may include a plurality of said unit dosage forms.
  • the pharmaceutical composition may be adapted for administration by any appropriate route, for example by the oral (including buccal or sublingual), rectal, nasal, topical (including buccal, sublingual or transdermal), vaginal or parenteral (mcluding subcutaneous, intramuscular, intravenous or intradermal) route.
  • Such compositions may be prepared by any method known in the art of pharmacy, for example by admixing the active ingredient with the carrier(s) or excipient(s) under sterile conditions.
  • compositions adapted for oral administration may be presented as discrete units such as capsules or tablets; as powders or granules; as solutions, syrups or suspensions (in aqueous or non-aqueous liquids; or as edible foams or whips; or as emulsions).
  • Suitable excipients for tablets or hard gelatine capsules include lactose, maize starch or derivatives thereof, stearic acid or salts thereof.
  • Suitable excipients for use with soft gelatine capsules include for example vegetable oils, waxes, fats, semi-solid, or liquid polyols etc.
  • excipients which may be used include for example water, polyols and sugars.
  • oils e.g. vegetable oils
  • oil-in-water or water in oil suspensions may be used to provide oil-in-water or water in oil suspensions.
  • compositions adapted for transdermal adrninistration may be presented as discrete patches intended to remain in intimate contact with the epidermis of the recipient for a prolonged period of time.
  • the active ingredient may be delivered from the patch by iontophoresis as generally described in Pharmaceutical Research, 3(6):318 (1986).
  • compositions adapted for topical administration maybe formulated as ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, sprays, aerosols or oils.
  • the compositions are preferably applied as a topical ointment or cream.
  • the active ingredient may be employed with either a paraffinic or a water-miscible ointment base.
  • the active ingredient maybe formulated in a cream with an oil-in-water cream base or a water-in-oil base.
  • compositions adapted for topical administration to the eye include eye drops wherein the active ingredient is dissolved or suspended in a suitable carrier, especially an aqueous solvent.
  • Pharmaceutical compositions adapted for topical administration in the mouth include lozenges, pastilles and mouth washes.
  • compositions adapted for rectal adrninistration may be presented as suppositories or enemas.
  • compositions adapted for nasal administration wherein the carrier is a solid include a coarse powder having a particle size for example in the range 20 to 500 microns which is administered in the manner in which snuff is taken, i.e. by rapid inhalation through the nasal passage from a container of the powder held close up to the nose.
  • Suitable compositions wherein the carrier is a liquid, for administration as a nasal spray or as nasal drops, include aqueous or oil solutions of the active ingredient.
  • Pharmaceutical compositions adapted for administration by inhalation include fine particle dusts or mists which may be generated by means of various types of metered dose pressurised aerosols, nebulisers or insufflators.
  • compositions adapted for vaginal adrninistration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations.
  • compositions adapted forparenteral administration include aqueous and non-aqueous sterile injection solution which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation substantially isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.
  • Excipients which may be used for injectable solutions include water, alcohols, polyols, glycerine and vegetable oils, for example.
  • compositions may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilised) condition requiring only the addition of the sterile liquid carried, for example water for injections, immediately prior to use.
  • sterile liquid carried, for example water for injections, immediately prior to use.
  • Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets.
  • compositions may contain preserving agents, solubilising agents, stabilising agents, wetting agents, emulsifiers, sweeteners, colourants, odourants, salts (substances of the present invention may themselves be provided in the form of a pharmaceutically acceptable salt), buffers, coating agents or antioxidants. They may also contain therapeutically active agents in addition to the substance of the present invention.
  • Dosages of the polypeptide, nucleic acid or antibody used in of the present invention can vary between wide limits, depending upon the disease or disorder to be treated, the age and condition of the individual to be treated, etc. and a physician will ultimately determine appropriate dosages to be used. This dosage may be repeated as often as appropriate. If side effects develop the amount and/or frequency of the dosage can be reduced, in accordance with normal clinical practice.
  • the biological sample can be obtained from any source, such as a serum sample or a tissue sample.
  • the biological sample may be obtained using a small intestinal biopsy.
  • kits comprising an antibody against a polypeptide as defined in the thirteenth aspect.
  • a kit may optionally comprise one or more of the following: (1) instructions for using the antibody for diagnosis, prognosis, therapeutic monitoring or any combination of these applications; (2) a labelled binding partner to the antibody; (3) a solid phase (such as a reagent strip) upon which the antibody is immobilised; and (4) a label or insert indicating regulatory approval for diagnostic, prognostic or therapeutic use or any combination thereof.
  • the anti- polypeptide antibody itself can be labelled with a detectable marker, e.g., a chemiluminescent, enzymatic, fluorescent, or radioactive moiety.
  • kits comprising a nucleic acid probe capable of hybridising to RNA as defined in the first aspect.
  • a kit comprising in one or more containers a pair of primers as defined in the fourth aspect (e.g., each in the size range of 6-30 nucleotides, more preferably 10-30 nucleotides and still more preferably 10-20 nucleotides) that under appropriate reaction conditions can prime amplification of at least the mutated portion of a nucleic acid molecule as defined in the first aspect, such as by polymerase chain reaction (see e.g., Innis et al, 1990, PCR Protocols, Academic Press, Inc., San Diego, CA), ligase chain reaction (see EP 320,308) use of Q ⁇ replicase, cyclic probe reaction, or other methods known in the art.
  • polymerase chain reaction see e.g., Innis et al, 1990, PCR Protocols, Academic Press, Inc., San Diego, CA
  • ligase chain reaction see EP 320
  • the invention provides methods for identifying agents, candidate compounds or test compounds that bind to a polypeptide as defined in the thirteenth aspect or have a stimulatory or inhibitory effect on the expression or activity of a polypeptide as defined herein.
  • the compounds of the invention include but are not limited to any compound, e.g., a small organic molecule, protein, peptide, antibody, nucleic acid, etc. that restores the profile towards normal with the proviso that such compounds or treatments include, but are not limited to, taxol, cyclophosphamide, tamoxifen, and doxorubacin.
  • symptoms of a disorder of lipid metabolism may be ameliorated by decreasing the level or activity of a polypeptide as defined in the thirteenth aspect by using nucleic acid sequences of the first aspect in conjunction with well-known gene "knock-out,” ribozyme or triple helix methods to decrease expression of the polypeptide.
  • ribozyme or triple helix molecules are used to modulate the activity, expression or synthesis of the nucleic acid sequence, and thus to ameliorate the symptoms of the disorder of lipid metabolism.
  • Such molecules may be designed to reduce or inhibit expression of a mutant SARA2 gene. Techniques for the production and use of such molecules are well known to those of skill in the art.
  • Endogenous polypeptide expression can also be reduced by inactivating or "knocking out" a mutated SARA2 gene as defined herein, or the promoter of such a gene, using targeted homologous recombination (e.g., see Smithies, et al, 1985, Nature 317:230-
  • a mutant SARA2 gene encoding a non-functional polypeptide (or a completely unrelated DNA sequence) flanked by DNA homologous to the endogenous gene (either the coding regions or regulatory regions of the gene encoding the polypeptide) can be used, with or without a selectable marker and/or a negative selectable marker, to transfect cells that express the target gene in vivo. Insertion of the DNA construct, via targeted homologous recombination, results in inactivation of the target gene.
  • RNA interference may be used to silence or inhibit expression of a nucleic acid molecule of the invention.
  • a further aspect provides a method for identifying agents (e.g. drug candidates or test compounds) that have an inhibitory effect on the expression of a nucleic acid molecule of the first or second aspect, or activity of a polypeptide of the thirteenth aspect, comprising contacting a nucleic acid molecule of the first or second aspect, or a polypeptide of the thirteenth aspect with a candidate agent, and determining if the agent inhibits expression of the nucleic acid molecule or the activity of the polypeptide
  • agents e.g. drug candidates or test compounds
  • the present invention provides a method of screening for an agent that interacts with Sarlb, the method comprising identifying an agent that interacts with a surface of Sarlb away from the Sec23-Sarl binding surface, the surface comprising the amino acid residues Proline 139, Glutamic acid 140, Arginine 146, Methionine 150, Serine 162, Isoleucine 163, Serine 164, Leucine 109, Alanine 125, Aspartic acid 116, Glutamic acid 113, Serine 117 and/or Isoleucine 80, the method comprising contacting Sarlb polypeptide with a candidate agent and determining whether the agent interacts with the surface.
  • the present invention provides a method of screening for an agent that interacts with a polypeptide of the present invention, the method comprising contacting a polypeptide of the invention with a candidate agent and determining whether the agent interacts with the polypeptide.
  • the method identifies an agent that interacts with the surface of the polypeptide away from the Sec23-Sarl binding surface.
  • the present invention provides the use of an agent identified using the above methods of screening in the manufacture of a medicament for the treatment and/or prophylaxis of a disorder of lipid metabolism.
  • CMRD In CMRD, AD, and CMRD with MSS there is a failure to absorb lipid from the intestine.
  • the consequences of this can be considered to be the reverse of the problems that lead to obesity, insulin resistance, type II diabetes, atheroscelerosis, dyslipidemia, and hyperlipidemia. Therefore, the identification of defective SARA2 gene in CMRD, AD, and CMRD with MSS leads to the suggestion that other disorders of lipid metabolism, such as obesity, insulin resistance, type II diabetes, atheroscelerosis, dyslipidemia, and hyperlipidemia can be prevented and/or treated by blocking and/or reducing normal Sarlb activity. By blocking Sarlb activity, CMRD may be mimicked and furthermore lipid absorption can be reduced.
  • a method for the prophylaxis and/or treatment of disorders of lipid metabolism comprising blocking and/or reducing Sarlb activity in a subject.
  • the disorders of lipid metabolism may be obesity, insulin resistance, type II diabetes, atheroscelerosis, dyslipidemia, and/or hyperlipidemia
  • Blocking and/or reducing of Sarlb activity may be carried out by: i) Decreasing transcription of Sarlb gene (SARA2); ii) Reducing mRNA levels; iii) Decreasing GTPase activity of Sarlb protein; or iv) Interfering with the interaction of Sarlb protein with other proteins that augment GTP hydrolysis, and chylomicron and very low density lipoprotein export from the intestinal absorption cell and hepatocyte, respectively.
  • SARA2 Decreasing transcription of Sarlb gene
  • Reducing mRNA levels iii) Decreasing GTPase activity of Sarlb protein
  • Decreased transcription of SARA2 may be achieved by interfering with transcription by, for example, interfering with the activity of specific transcription factors thereby up-regulating or down-regulating Sarlb activity. Such methods are well known on the art.
  • symptoms of a disorder of lipid metabolism and in particular obesity, insulin resistance, type II diabetes, atheroscelerosis, and hyperlipidemia maybe ameliorated by decreasing the level or activity of a Sarlb polypeptide by using well-known gene "knock-out,” ribozyme or triple helix methods to decrease expression.
  • ribozyme or triple helix molecules are used to modulate the activity, expression or synthesis of the nucleic acid sequence encoding Sarlb (SARA2), and thus to ameliorate the symptoms of the disorder of lipid metabolism.
  • SARA2 nucleic acid sequence encoding Sarlb
  • Such molecules may be designed to reduce or inhibit expression of SARA2. Techniques for the production and use of such molecules are well known to those of skill in the art.
  • Endogenous polypeptide expression can also be reduced by inactivating or "knocking out” SARA2, or the promoter of such a gene, using targeted homologous recombination (e.g., see Smithies, et al, 1985, Nature 317:230-234; Thomas & Capecchi, 1987, Cell 51:503-512; Thompson et al, 1989, Cell 5:313-321; and Zijlstra et al, 1989, Nature 342:435-438).
  • targeted homologous recombination e.g., see Smithies, et al, 1985, Nature 317:230-234; Thomas & Capecchi, 1987, Cell 51:503-512; Thompson et al, 1989, Cell 5:313-321; and Zijlstra et al, 1989, Nature 342:435-438.
  • a Sarlb gene encoding a non- functional polypeptide (or a completely unrelated DNA sequence) flanked by DNA homologous to the endogenous gene (either the coding regions or regulatory regions of the gene encoding the polypeptide) can be used, with or without a selectable marker and or a negative selectable marker, to transfect cells that express the target gene in vivo. Insertion of the DNA construct, via targeted homologous recombination, results in inactivation of the target gene.
  • Such approaches are particularly suited in the agricultural field where modifications to ES (embryonic stem) cells can be used to generate animal offspring with an inactive target gene (e.g., see Thomas & Capecchi, 1987 and Thompson, 1989, supra).
  • RNA interference may be used to silence or inhibit expression of SARA2 gene.
  • mRNA levels may be reduced by, for example, using antisense nucleic acid molecules.
  • expression of Sarlb maybe inhibited by use of antisense nucleic acid molecules.
  • the antisense nucleic acid molecule is capable of hybridising by virtue of some sequence complementarity to a portion of an RNA (preferably mRNA) derived from the nucleic acid sequence of Sarlb.
  • the antisense nucleic acid may be complementary to a coding and/or non-coding region of a mRNA derived from the Sarlb.
  • Such antisense nucleic acids have utility as compounds that inhibit expression, and can be used in the treatment and/or prevention of disorders of lipid metabolism, and particularly obesity, insulin resistance, type II diabetes, atheroscelerosis, and hyperlipidemia.
  • a hybridising nucleic acid molecule of the present invention may have a high degree of sequence identity along its length with a nucleic acid molecule for Sarlb (e.g. at least 50%, at least 75% or at least 90% or 95% sequence identity).
  • a nucleic acid molecule for Sarlb e.g. at least 50%, at least 75% or at least 90% or 95% sequence identity.
  • the present invention provides a method for identifying agents (e.g. drug candidates or test compounds) that have an inhibitory effect on the expression or activity of Sarlb polypeptide comprising contacting SARA2 gene or Sarlb polypeptide with candidate agents, and selecting those agents which inhibit expression of SARA2 gene or activity of Sarlb polypeptide.
  • agents, candidate compounds or test compounds of the present invention include, but are not limited to, nucleic acids (e.g., DNA and RNA), carbohydrates, lipids, proteins, peptides, peptidomimetics, small molecules and other drugs.
  • Agents can be obtained using any of the numerous approaches in combinatorial library methods known in the art, including: biological libraries; spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the "one-bead one-compound” library method; and synthetic library methods using affinity chromatography selection.
  • biological library approach is limited to peptide libraries, while the other four approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds (Lam, 1997, Anticancer Drug Des. 12:145; U.S. Patent No. 5,738,996; and U.S. Patent No.5,807,683, each of which is incorporated herein in its entirety by reference).
  • Libraries of compounds maybe presented, e.g., presented in solution (e.g., Houghten, 1992, Bio/Techniques 13:412-421), or on beads (Lam, 1991, Nature 354:82-84), chips (Fodor, 1993, Nature 364:555-556), bacteria (U.S. Patent No. 5,223,409), spores (Patent Nos. 5,571,698; 5,403,484; and 5,223,409), plasmids (Cull et al., 1992, Proc.
  • agents are identified in a cell-based assay system.
  • cells expressing Sarlb are contacted with an agent, such as a drug candidate, or a control and the ability of the agent to inhibit Sarlb activity, e.g. by interacting with Sarlb, is studied.
  • this assay may be used to screen a plurality (e.g. a library) of candidate compounds.
  • the cell for example, can be of prokaryotic origin (e.g., E. coli) or eukaryotic origin (e.g., yeast or mammalian).
  • the Sarlb or the candidate compound is labeled, for example with a radioactive label (such as 32 P, 35 S or 125 I) or a fluorescent label (such as fluorescein isothiocyanate, rhodamine, phycoerythrin, phycocyanin, allophycocyanin, o-phthaldehyde or fluorescamine) to enable detection of an interaction between Sarlb and an agent, such as a drug candidate.
  • a radioactive label such as 32 P, 35 S or 125 I
  • a fluorescent label such as fluorescein isothiocyanate, rhodamine, phycoerythrin, phycocyanin, allophycocyanin, o-phthaldehyde or fluorescamine
  • an agent such as a drug candidate.
  • the ability of the candidate compound to interact directly or indirectly with Sarlb can be determined by methods known to those of skill in the art. For example, the interaction between an agent and Sarlb can be determined by flow
  • Inhibition of Sarlb can be determined by contacting cells expressing Sarlb with an agent, such as a drug candidate; and deteirnining whether secretion of chylomicrons and/or very low density lipoproteins is decreased in the presence of the agent.
  • an agent such as a drug candidate
  • agents are identified in a cell-free assay system.
  • a native or recombinant Sarlb is contacted with an agent or a control and the ability of the agent to inhibit Sarlb activity, e.g. by interacting with Sarlb is determined.
  • this assay maybe used to screen a plurality (e.g. a library) of agents.
  • the Sarlb is first immobilized, by, for example, contacting the Sarlb with an immobilized antibody which specifically recognizes and binds it, or by contacting a purified preparation of the Sarlb with a surface designed to bind proteins.
  • the Sarlb may be partially or completely purified (e.g., partially or completely free of other polypeptides) or part of a cell lysate.
  • the Sarlb may be a fusion protein comprising the Sarlb or a biologically active portion thereof and a domain such as glutatMonine-S-transferase.
  • the Sarlb can be biotinylated using techniques well known to those of skill in the art (e.g., biotinylation kit, Pierce Chemicals; Rockford, IL). The ability of the agent to interact with Sarlb can be determined by methods known to those of skill in the art.
  • agents that modulate i.e., upregulate or downregulate the expression of Sarlb are identified by contacting cells (e.g., cells of prokaryotic origin or eukaryotic origin) expressing Sarlb gene (SARA2) with a candidate agent or a control (e.g., phosphate buffered saline (PBS)) and deteimining the expression of SARA2 gene or mRNA encoding Sarlb.
  • cells e.g., cells of prokaryotic origin or eukaryotic origin
  • PBS phosphate buffered saline
  • the level of expression of SARA2 gene or mRNA encoding Sarlb in the presence of the candidate agent is compared to the level of expression of the S ARA2 gene or mRNA encoding the Sarlb in the absence of the candidate agent (e.g., in the presence of a control).
  • the candidate agent can then be identified as a modulator of the expression of Sarlb.
  • expression of Sarlb or mRNA encoding Sarlb is significantly less in the presence of the candidate agent than in its absence, the candidate agent is identified as an inhibitor of the expression of Sarlb or mRNA encoding Sarlb.
  • the level of expression of Sarlb or the mRNA that encodes it can be determined by methods known to those of skill in the art. For example, mRNA expression can be assessed by Northern blot analysis or RT-PCR, and protein levels can be assessed by western blot analysis.
  • a method of identifying agents that modulate the activity of Sarlb comprising contacting a preparation containing Sarlb, or cells (e.g., prokaryotic or eukaryotic cells) expressing the Sarlb with a test agent or a control and determining the ability of the test agent to modulate (e.g., stimulate or inhibit) the activity of Sarlb.
  • the activity of Sarlb may be assessed by detecting GTP hydrolysis, the interaction of Sarlb with Sec23/24 and/or Sec 13/31, or by measuring vesicle fusion. Based on the present description, techniques known to those of skill in the art can be used for measuring these activities.
  • the method may comprise: i) contacting a preparation containing Sarlb, or cells (e.g., prokaryotic or eukaryotic cells) expressing Sarlb with a test agent or a control, and GTP; ii) measuring GTP hydrolysis; and iii) determining whether GTP hydrolysis is affected in the presence of the agent.
  • the GTP is labelled GTP.
  • the GTP may be fluorescently or radioactively labelled.
  • a radioactive label may be 32 P
  • the GTP hydrolysis is measured by detecting release of labelled phosphate from the GTP.
  • control is provided to ensure that the agent(s) are specific to Sarlb.
  • the control may comprise contacting the agent(s) with a further GTPase and measuring
  • the method comprises: i) contacting an agent with Sarlb and Sec23/24 and or Sarlb and Seel 3/31; and ii) detecting whether the agent inhibits the interaction.
  • the interaction between Sarlb and Sec23/24 and/or Sarlb and Sec 13/31 can be measured using methods well known in the art.
  • One such method is by studying vesicle fusion. This may be determined through the use of fluorescent probes to determine whether vesicles fuse in the presence of the agent(s).
  • agent is used herein to describe a wide variety of physical, chemical or biological factors.
  • physical agents include, without limitation, the diet of a subject, a change in temperature or humidity, exposure to ultraviolet radiation and the like.
  • Biological and chemical agents include exogenous factors such as pharmaceutical compounds (including candidate compounds and test compounds), toxic compounds, proteins, peptides, chemical compositions, natural pathogens, such as microbial agents including bacteria, viruses and lower eukaryotic cells such as fungi, yeast and simple multicellular organisms, as well as endogenous factors which occur naturally in the body, including, without limitation, hormones, enzymes, receptors, ligands and the like, which may or may not be recombinant.
  • the present invention provides the use of an agent identified using the above methods in the manufacture of a medicament for the prophylaxis and/or treatment of a disorder of lipid metabolism.
  • the disorder may be obesity, insulin resistance, type Ji diabetes, atheroscelerosis, dyslipidemia, and/or hyperlipidemia.
  • the present invention provides a method of screening for an agent that interacts with a polypeptide of the present invention.
  • the method identifies an agent that interacts with the surface of the polypeptide away from the Sec23-Sarl binding surface.
  • the present invention provides the use of an agent identified using the above method of screening in the manufacture of a medicament for the prophylaxis and/or treatment of a disorder of lipid metabolism.
  • Figure 1 provides a) the nucleic acid sequence (SARA2) encoding Sarlb, and b) the amino acid sequence for Sarlb;
  • Figure 2 provides the nucleic acid sequence of mutated SARA2, the mutation being defined in Table 1;
  • Figure 3 provides the amino acid sequence encoded by the nucleic acid sequence of Figure 2;
  • Figure 4 provides the nucleic acid sequence of mutated SARA2, the mutation being defined in Table 1 ;
  • Figure 5 provides the amino acid sequence encoded by the nucleic acid sequence of Figure 4.
  • Figure 6 provides the nucleic acid sequence of mutated SARA2, the mutation being defined in Table 1;
  • Figure 7 provides the amino acid sequence encoded by the nucleic acid sequence of Figure 6;
  • Figure 8 provides the nucleic acid sequence of mutated SARA2, the mutation being defined in Table 1;
  • Figure 9 provides the amino acid sequence encoded by the nucleic acid sequence of Figure 8.
  • Figure 10 provides the nucleic acid sequence of mutated SARA2, the mutation being defined in Table 1;
  • Figure 11 provides the amino acid sequence encoded by the nucleic acid sequence of Figure 10;
  • Figure 12a provides the nucleic acid sequence of mutated SARA2, the mutation being defined in Table 1;
  • Figure 12b provides the nucleic acid sequence resulting from the mutated sequence in Figure 12a;
  • Figure 12c provides an alternative nucleic acid sequence resulting from the mutated sequence in Figure 12a;
  • Figure 13a provides the amino acid sequence encoded by the nucleic acid sequence of Figure 12b;
  • Figure 13b provides the amino acid sequence encoded by the nucleic acid sequence of Figure 12c;
  • Figure 14 provides the nucleic acid sequence of mutated SARA2, the mutation being defined in Table 1;
  • Figure 15 provides the amino acid sequence encoded by the nucleic acid sequence of Figure 14;
  • FIG 16 Pedigrees, linkage analysis, and fine-mapping of the Anderson's Disease (AD), Chylomicron Retention Disease (CMRD) with Marinesco-Sjogren Syndrome
  • CMRD/MSS gene locus. Fasting plasma total cholesterol (TC) and apolipoprotein (apo)B levels are shown. Microsatellite loci spanning an interval of XcM are shown on the left. Polymorphic DNA markers D5S2110 and D5S816 delineate a 4cM region of homozygosity (affected sibs, families 1, 2, 5 and 6) and is boxed. Sarlb resides between D5S2115 and D5S816 on the physical map (http://www.ensembl.orR). The affected and unaffected chromosomes are represented by filled-in and blank bars, respectively. Parents of the affected children are depicted as obligate carriers. Squares, males; circles, females; double lines, consanguineous matings; filled squares and circles, affected individuals.
  • FIG 17 Mutation analysis of the Sarlb gene in Chylomicron Retention Disease, Anderson's Disease (AD), Chylomicron Retention Disease (CMRD) with Marinesco- Sjogren Syndrome (CMRD/MSS). Sequence chromatographs showing the mutations and the translated amino acids of mutant alleles. Amino acids shown in magenta represent missense mutations.
  • the Sarlb gene of patient 3 family lb, AD
  • also contains the G37R missense mutation on both alleles sequence trace not shown.
  • the D 137N missense mutation was also present on one allele in patient H/l of family
  • CMRD complementary metal-oxide-semiconductor
  • CMRD and MSS may produce a mRNA species that lacks exon 6 sequences, which encode amino acids 117-160 of Sarlb. Residues that differ between human Sarlb and Sarla are displayed in green. Residues that contribute to the Sarlp-Sec23 interface of the Sari- are shown in light blue. The two residues highlighted in red differ between human Sarlb and hamster Sari .
  • the secondary structure elements are based on the X-ray crystal structure of hamster Sari (1F6B_B). Blue cylinders represent ⁇ -helices. Yellow arrows depict ⁇ -strands.
  • Loops are shown in grey and residues with unassigned coordinates by a dashed line.
  • C Ribbon representation of hamster Sarl-GDP.
  • Sari has a structural core of six ⁇ -strands (yellow) that are sandwiched between three ⁇ - helices (blue) on either side.
  • GDP and the four residues (Gly 37 , Asp 137 , Ser 179 and L 181 ) mutated in CMRD and AD are depicted in a stick representation.
  • GDP atoms green, carbon; blue, nitrogen; oxygen, red and phosphorous, yellow.
  • the location of the magnesium ion is shown as a grey sphere.
  • Gly 37 (Gly 37 , Asp 137 , Ser 179 and Leu 181 ) are shown in: green, carbon; blue, nitrogen; oxygen, red and phosphorous, yellow. Gly 37 sits at the base of the nucleotide binding site in contact with the ribose ring of GDP. Asp 137 forms three hydrogen-bonds, two with
  • FIG 19 Expression of Sarlb and Sarla in human tissues.
  • the coding sequences of Sarlb and Sarla were amplified from control cDNA (MTC panel I, BD Biosciences, ) using TITANIUMTM Taq DNA Polymerase, and radiolabelled (Rediprime II DNA labelling system, Amersham, Uppsala), and hybridised to the same multiple tissue northern blot (BD Biosciences,). B-actin was used as a loading control. The blot was stripped between hybridisations. Numbers indicate the sizes of Standard RNA in kilobases (kb).
  • Figure 20 Effect of high levels of human Sarla and Sarlb expression on the secretion of apoB48 and apoBlOO - containing lipoproteins from stable McA- RH7777 cell lines.
  • the Sarlb gene encodes an ADP-ribosylation factor (AFR) related small GTPase protein component of the cytoplasmic coat protein ⁇ complexes (COPH) vesicle coat, which is involved in endoplasmic reticulum (ER) to Golgi apparatus transport of proteins.
  • AFR ADP-ribosylation factor
  • COH cytoplasmic coat protein ⁇ complexes
  • This gene lies between D5S2115 and D5S816 on the physical map (Fig 16.).
  • the coding sequences and consensus splice site sequences were amplified from genomic DNA by polymerase chain reaction (PCR) in all patients and family members.
  • CMRD Chylomicron Retention Disease
  • AD Anderson's disease
  • CMRD/MSS chylomicron retention disease with Marinesco-Sjogren Syndrome
  • the COP ⁇ machinery for transport of proteins between the endoplamic reticulum (E R) and the Golgi apparatus is highly conserved between yeast and mammals.
  • Sari is involved in three critical steps in this process, which processively require GTP binding and hydrolysis.
  • First, Sari possesses an amino terminal membrane anchor (in common with the ARFs) that is retracted in the GDP bound state and exposed in the GTP bound state.
  • On GTP binding the release of this membrane anchor by Sari increases membrane binding, and enhances the affinity of binding of Sec23/24 to Sari (Fig 18F).
  • the Sarl-Sec23/24 complex forms an extensive interaction with the ER membrane to create the prebudding complex.
  • Sec23 is the Sarl-GTPase activating protein (GAP).
  • Sarlb will have a marked effect in the region of guanine nucleotide binding on the local protein fold (Fig.l8C, D).
  • NKxD 137 of all small GTP-binding proteins (Table 2, Fig. 17, Fig, 18B).
  • Gly 37 sits at the base of the guanidine diphosphate (GTP) and guanidine triphosphate (GTP) binding cleft of the Sari family of GTPase, in contact with the ribose ring of the guanine base (Fig. 18C, D).
  • An Arg residue at this position (family 1, AD) would almost certainly hinder the binding of guanine nucleotide by Sari, either through steric hindrance or more likely, changes in the geometry of the GDP/GTP binding cleft.
  • the Asp 137 to Asn mutation (families 2 and 3, CMRD), although conservative, results in the loss of one of these hydrogen bonds, which will almost certainly affect the affinity of Sarlb for guanine nucleotides (Fig.l ⁇ D).
  • the Sari -GDP/GTP structures also indicate that three further missense mutations (Ser for Arg, S 179R; Ser for He, S 1791;
  • Ser 179 forms a hydrogen bonding network between Asp 137 and the main chain amide of Lys 182 (Fig. 18D). These interactions link two ⁇ -turns (amino acids 136-140 and 178-183) that are critical for the overall fold of the nucleotide binding cleft. Mutation of Ser 179 to either
  • Arg or lie would disrupt the hydrogen bond network and significantly affect the geometry of the nucleotide binding cleft.
  • the Leu 181 to Pro missense mutation would also perturb the local geometry of the ⁇ -turn formed by amino acids 178-183, and abrogate the hydrophobic packing interaction between Leu 181 and the purine ring of GDP/GTP (Fig 18D).
  • the mutant allele encodes a protein with twelve aberrant amino acids including three highly conserved residues (Gin 195 , Tyr 196 , He 197 ) at its C-terminal end (Fig. 18B).) which along with the N-terminal is involved in the initial interaction of Sari with the membrane.
  • This family there is very limited transport of Cms to the Golgi apparatus.
  • a splice site mutation was identified on both alleles of the Sarlb gene in two patients (family 6, ITJ1 and JJI2) with CMRD and MSS (Fig. 17, Table 2).
  • the mutation may produce a shorter transcript that encodes 119 amino acids (Table 2), or an mRNA species that lacks exon 6 sequences (amino acids 117-160) (Fig.18B) . This would have a massive impact on the structure and function of Sarlb, and since the gene is expressed in other tissues (Fig. 19a,b) including muscle and brain may well explain the musculo-skeletal and neurological abnormalites in CM with MSS.
  • COP ⁇ vesicles In the liver large lipid droplets accumulate in the terminal part of the smooth ER next to the Golgi apparatus, and in the Golgi apparatus NLDL is confined to the terminal saccules of the Golgi stack. Sari alone can initiate membrane cargo selection before recruitment of Sec23/24 and Secl3/31 through the formation of specialised export domains and the balance between vesicle and tubule formation.
  • procollagen is 200 nm in length.
  • Serlb for lipoproteins we mapped the 20 variant amino acids between Sarla and Sarlb to the hamster Sari crystal structure. These variant residues mainly fall on one surface of the protein away from the Sec23-Sarl binding surface, which appear to be highly conserved in Sari as well as Sec23. These residues and this surface are not particularly hydrophobic as might be anticipated for a membrane associated or protein-protein interaction domain. However, this surface would appear to provide the constraints, which mediate the selection of this very unusual lipoprotein cargo.
  • An understanding of the molecular basis for this process may indicate a novel therapeutic approach to obesity, and to postprandial hyperlipidemia, a condition that confers a high risk of atherosclerosis.
  • a whole-genome linkage analysis was performed using X polymorphic DNA markers at ⁇ 8cM intervals (Weber Human Screening Set Version 9, Research Genetics, Inc. Huntsville), followed by an additional 49 genetic markers to evaluate the X genomic regions that could not be excluded as containing the CMRD, AD and CMRD+MSS gene in the initial screen. D and D were the only markers to segregate with affected status in all families. Markers were genotyped in all family members from pedigrees 1-6.
  • Caco-2 cells provide a well-characterised model for the in vitro study of Cm production.
  • Caco-2 cells spontaneously differentiate in culture into enterocyte-like cells, with polarised apical and basolateral surfaces, brush-border microvilli and tight junctions. The differentiation process is accompanied by increased expression of apoB48 and 100, and increased secretion of VLDL and Cm.
  • differentiated Caco-2 cells emulate in vivo behaviour by increasing Cm secretion in response to oleic acid, and decreasing secretion in response to Pluronic L81.
  • McA- RH7777 cells are a commonly used hepatoma cell line that produces apoB48- containing lipoproteins, as well as VLDL-apoB 100.
  • Sarlb therefore promotes the secretion of hepatic apoB- containing lipoproteins (i.e. very low density lipoproteins), as well as chylomicrons.
  • hepatic apoB- containing lipoproteins i.e. very low density lipoproteins
  • chylomicrons i.e. very low density lipoproteins
  • lipid metabolism disorders such as dyslipidemia and/or hyperlipidemia associated with obesity, insulin resistance, type H diabetes, and atheroscelerosis, there would therefore be a need to reduce Sarlb activity so that less lipid is absorbed, and released into blood in chylomicrons and very low density lipoproteins
  • the nucleic acid sequence encoding Sarlb (designated SARA2) is given in Figure la.
  • the amino acid sequence for Sarlb is given in Figure lb.
  • Sarlb protein is a small GTPase and that the process of GTP hydrolysis is necessary for the movement of chylomicrons between the endoplasmic reticulum and the Golgi apparatus.
  • GNP GDP/GTP nucleotide
  • COPII cytoplasmic coat II complexes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des molécules d'acide nucléique isolées ou recombinantes présentant une ou plusieurs mutations liées à des troubles du métabolisme des lipides, tels que la maladie de retenue des chylomicrons (CMRD), la maladie d'Andersen (AD), la maladie de retenue des chylomicrons associée au syndrome de Marinesco-Sjogren (CMRD associé à MSS), l'obésité, la résistance à l'insuline, le diabète de type II, l'athérosclérose, la dyslipidémie, et l'hyperlipidémie. Elle concerne également les polypeptides codés par ces molécules d'acide nucléique ayant subi une mutation. Elle concerne également le diagnostic, la prophylaxie et/ou le traitement de maladies du métabolisme des lipides.
PCT/GB2003/004816 2002-11-07 2003-11-07 Troubles du metabolisme des lipides Ceased WO2004042064A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003279461A AU2003279461A1 (en) 2002-11-07 2003-11-07 Disorders of lipid metabolism

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
GB0226039A GB0226039D0 (en) 2002-11-07 2002-11-07 Conditions of lipid excess
GB0226039.6 2002-11-07
GB0226152.7 2002-11-08
GB0226152A GB0226152D0 (en) 2002-11-08 2002-11-08 Conditions of lipid excess
GB0305463A GB0305463D0 (en) 2003-03-10 2003-03-10 Disorders of lipid metabolism
GB0305463.2 2003-03-10
GB0323689.0 2003-10-09
GB0323689A GB0323689D0 (en) 2003-10-09 2003-10-09 Disorders of lipid metabolism

Publications (2)

Publication Number Publication Date
WO2004042064A2 true WO2004042064A2 (fr) 2004-05-21
WO2004042064A3 WO2004042064A3 (fr) 2004-12-02

Family

ID=32314923

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2003/004816 Ceased WO2004042064A2 (fr) 2002-11-07 2003-11-07 Troubles du metabolisme des lipides

Country Status (2)

Country Link
AU (1) AU2003279461A1 (fr)
WO (1) WO2004042064A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10188691B2 (en) * 2016-05-27 2019-01-29 Synthex, Inc. Protein interfaces

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DANNOURA A H ET AL: "Anderson's disease: exclusion of apolipoprotein and intracellular lipid transport genes." ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY. OCT 1999, vol. 19, no. 10, October 1999 (1999-10), pages 2494-2508, XP002292952 ISSN: 1079-5642 *
ESPENSHADE PETER J ET AL: "Sterols block binding of COPII proteins to SCAP, thereby controlling SCAP sorting in ER" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 99, no. 18, 3 September 2002 (2002-09-03), pages 11694-11699, XP002293708 ISSN: 0027-8424 *
HUSSAIN M M: "A proposed model for the assembly of chylomicrons." ATHEROSCLEROSIS. JAN 2000, vol. 148, no. 1, January 2000 (2000-01), pages 1-15, XP002292733 ISSN: 0021-9150 *
JONES BETHAN ET AL: "Mutations in a Sar1 GTPase of COPII vesicles are associated with lipid absorption disorders." NATURE GENETICS. MAY 2003, vol. 34, no. 1, May 2003 (2003-05), pages 29-31, XP002292736 ISSN: 1061-4036 *
KUGE OSAMU ET AL: "Sar1 promotes vesicle budding from the endoplasmic reticulum but not Golgi compartments" JOURNAL OF CELL BIOLOGY, vol. 125, no. 1, 1994, pages 51-65, XP002292735 ISSN: 0021-9525 *
SHOULDERS CAROL C ET AL: "The intracellular transport of chylomicrons requires the small GTPase, Sar1b." CURRENT OPINION IN LIPIDOLOGY. APR 2004, vol. 15, no. 2, April 2004 (2004-04), pages 191-197, XP002292737 ISSN: 0957-9672 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10188691B2 (en) * 2016-05-27 2019-01-29 Synthex, Inc. Protein interfaces

Also Published As

Publication number Publication date
WO2004042064A3 (fr) 2004-12-02
AU2003279461A1 (en) 2004-06-07
AU2003279461A8 (en) 2004-06-07

Similar Documents

Publication Publication Date Title
EP1493033B1 (fr) Sc6 destinée au diagnostic et traitement de carcinome mammaire
Gros-Louis et al. A frameshift deletion in peripherin gene associated with amyotrophic lateral sclerosis
US8252578B2 (en) Juvenile hemochromatosis gene (HFE2A) cleavage products and uses thereof
EP1325338A2 (fr) Diagnostic et le traitement de la maladie d'alzheimer
JP2010524434A (ja) Ｋｃｎｈ２の統合失調症関連アイソフォームおよび抗精神病薬の開発
JP2003284574A (ja) 核酸分子、ポリペプチド、ならびにアルツハイマー病の診断および処置を含むそれらの使用
AU2001233929A1 (en) Use of breast cancer associated membrane proteins (BCMP) for treatment, prophylaxis and diagnosis of breast cancer
WO2001062784A2 (fr) Proteines
WO2004018633A2 (fr) Acides nucleiques et proteines abca13 : utilisations
JP2008522162A (ja) Ｍｅｒの診断用および治療用の作用薬
WO2002046221A2 (fr) Proteines
AU750543B2 (en) The protein tyrosine kinase substrate LAT and its use in the identification of (ant)agonists of the kinase
WO2001063290A1 (fr) Bcmp 7 en tant que marqueur pour le diagnostic du cancer du sein
WO2004042064A2 (fr) Troubles du metabolisme des lipides
WO2001062785A2 (fr) Proteines, genes et leur utilisation dans le diagnostic et le traitement de la schizophrenie
US20040254132A1 (en) Ovary-specific genes and proteins
Chan et al. Structure, function, molecular genetics, and epidemiology of apolipoprotein B
WO2004005338A1 (fr) Peptides secretes
KR101338885B1 (ko) Mgc4504의 용도
EP1395830B1 (fr) Proteine bcmp-101 associee au cancer
US7166433B2 (en) Transductin-1 and transductin-2 and applications to hereditary deafness
WO2004039979A1 (fr) Moyens et methodes permettant de diagnostiquer et de traiter une epilepsie idiopathique generalisee
Hunter Molecular investigations of the CMT4D gene N-myc downstream-regulated gene 1 (NDRG1)
US20040166517A1 (en) Cancer associated protein
JP2008517592A (ja) スクリーニングアッセイ

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP